Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Merck paid an undisclosed sum to Elsevier to produce several ... after reviewing two issues of the publication obtained by The Scientist. "But even for someone as jaded as me, this is a new wrinkle." ...

It is a cancer drug her company discovered—one that has made her the face of a rising pharmaceutical star. When Xia founded ...

The Merck Future Insight prize was established on the occasion of Merck’s 350th anniversary in 2018 to honour and enable pioneering scientists who are striving to solve some of the biggest ...

The Bayesian Back End software (in short BayBE) represents the development of an AI-assisted experimental planner by Merck scientists across the entire group. The project has grown into an ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...

and opportunities to pilot their technologies in collaboration with discovery and clinical scientists at Merck. Funding for the MDSS is being contributed by McKesson Ventures, Merck Global Health ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data sho ...

Join Michael Hafey, Principal Scientist at Merck, as he discusses how to utilize a two-tiered in vitro assay approach to derisk compounds that inhibit bile-salt transport protein, a known mechanism ...